Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1217486-61-7
Formula :	C₁₉H₂₂F₃N₅O₂S
M.W :	441.47
SMILES Code :	O=C(N1[C@H](C(N)=O)CCC1)NC2=NC(C)=C(C3=CC(C(C)(C)C(F)(F)F)=NC=C3)S2
Synonyms :	BYL-719; NVP-BYL719
MDL No. :	MFCD22417085
InChI Key :	STUWGJZDJHPWGZ-LBPRGKRZSA-N
Pubchem ID :	56649450

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

HEK293T cells	500nM	Overnight	To identify the methyltransferase responsible for methylating K1330 of KMT2D	PMC11265541
CAL-33	0.5 μM	30 min	To study the effect of Alpelisib on the PI3K signaling pathway, results showed that Alpelisib inhibited the PI3K signaling pathway	PMC9126298
MCF7 cells	250 nM	48 h	To investigate the effect of Alpelisib on cell cycle proteins, results showed inhibitory effect in MCF7 cells	PMC10680093
T47D cells	250 nM	48 h	To investigate the effect of Alpelisib on cell cycle proteins, results showed stronger inhibitory effect in T47D cells	PMC10680093
MCF7 MAGI1 KO cells	2 µM	72 h	To investigate the effect of Alpelisib on the activation of DNA repair proteins in MCF7 MAGI1 KO cells, results showed that DNA repair proteins (e.g., DNA-PKs, phospho-ATM (S1981), phospho-p95/NSB1 (S343), and XLF) were upregulated after Alpelisib treatment.	PMC10417439
MCF7 MAGI1 KO cells	2 µM	72 h	To study the effect of Alpelisib in combination with Fulvestrant on MCF7 MAGI1 KO cells, results showed that the combination treatment significantly reduced cell viability.	PMC10417439
HK2 cells	10 µM	16 h	Reduced aberrant actin polymerization, improved endocytic defect	PMC7550850
OcrlY/- mouse PTCs	10 µM	16 h	Restored stress fiber architecture, reduced endosomal actin staining	PMC7550850
MCF7	0.1 μM	6 days	To validate the effect of combining PI3K α inhibitor alpelisib with MCL1 inhibitor s63845, the results showed that the combination was more efficacious than each drug alone and induced more apoptosis	PMC8744502
T47D	0.1 μM	6 days	To validate the effect of combining PI3K α inhibitor alpelisib with MCL1 inhibitor s63845 and BCL-2/BCL-XL inhibitor navitoclax, the results showed that the combination was more efficacious than each drug alone and induced more apoptosis	PMC8744502

Mice	MCF7 human breast cancer xenograft model	Oral	25 mg/kg	Once daily for the indicated times	To evaluate the antitumor activity of SMYD2 knockdown combined with Alpelisib	PMC11265541
Mice	MCF7 xenograft models	Oral	125 nM	6 days a week for 3 weeks	To investigate the inhibitory effect of Alpelisib on tumor growth in vivo, results showed partial inhibition in RB-deficient tumors	PMC10680093
mouse	OcrlY/- mouse model	oral gavage	50 mg/kg	daily for 6 weeks	Reduced endosomal actin staining, improved endocytic function, reduced proteinuria	PMC7550850
Mice	Orthotopic osteosarcoma model	Oral	50 mg/kg	Daily for 7 days	Evaluate the anti-tumor effect of Alpelisib in the mouse orthotopic osteosarcoma model, results showed that Alpelisib significantly inhibited tumor growth	PMC10162498
nude mice	xenograft tumor model	oral	12.5 mg/kg	once daily	The combination of Alpelisib and EZH inhibitor Tazemetostat induces regression of xenograft tumors harboring a PIK3CA helical domain mutation, but not tumors with either a WT PIK3CA or a PIK3CA kinase domain mutation.	PMC9007954

{[proInfo.proName]}

CAS No.: 1217486-61-7

{[proInfo.proName]}

CAS No.: 1217486-61-7

Alternative Products

Product Details of Alpelisib

Safety of Alpelisib

Related Pathways of Alpelisib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT02167854	Breast Cancer	Phase 1	Active, not recruiting	June 2019	United States, New Jersey ... More >> Memorial Sloan Kettering at Basking Ridge Basking Ridge, New Jersey, United States, 07920 Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States, 07748 United States, New York Memorial Sloan Kettering Commack Commack, New York, United States, 11725 Memoral Sloan Kettering Westchester Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering Rockville Centre Rockville Centre, New York, United States, 11570 Less <<
NCT02734615	Advanced or Metastatic ER+ Bre... More >>ast Cancer Less <<	Phase 1	Recruiting	October 30, 2020	United States, Maryland ... More >> Novartis Investigative Site Recruiting Baltimore, Maryland, United States, 21287 United States, Massachusetts Massachusetts General Hospital Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Dejan Juric, MD 617-726-6500 Juric.Dejan@mgh.harvard.edu Contact: Meghan Miles 617-726-6500 MEMILES@mgh.harvard.edu Principal Investigator: Dejan Juric, MD United States, New York Novartis Investigative Site Recruiting New York, New York, United States, 10021 Contact: Alexandra Burleigh 646-422-4394 burleiga@mskcc.org Principal Investigator: Komal Jhaveri United States, Texas Novartis Investigative Site Recruiting Houston, Texas, United States, 77030 Contact: Daniela Westerhold diwesterhold@mdanderson.org Principal Investigator: Rachel M Layman Belgium Novartis Investigative Site Recruiting Bruxelles, Belgium, 1200 Canada, Ontario Novartis Investigative Site Recruiting Toronto, Ontario, Canada, M5G 2M9 France Novartis Investigative Site Recruiting Lyon Cedex, France, 69373 Italy Novartis Investigative Site Recruiting Milano, MI, Italy, 20133 Novartis Investigative Site Recruiting Milano, MI, Italy, 20141 Japan Novartis Investigative Site Recruiting Koto-ku, Tokyo, Japan, 135 8550 Singapore Novartis Investigative Site Recruiting Singapore, Singapore, 169610 Spain Novartis Investigative Site Recruiting Barcelona, Catalunya, Spain, 08036 Novartis Investigative Site Recruiting Madrid, Spain, 28007 Less <<
NCT03138070	Head and Neck Squamous Cell Ca... More >>ncer Less <<	Not Applicable	Recruiting	May 2020	Canada, Ontario ... More >> London Health Sciences Centre, London Regional Cancer Program Recruiting London, Ontario, Canada, N6A 4L6 Contact: Anthony Nichols 519-685-8500 ext 58804 anthony.nichols@lhsc.on.ca Contact: Shamim Mortuza 519-685-8500 ext 58618 shamim.mortuza@lhsc.on.ca Less <<
NCT01602315	Recurrent Head and Neck Squamo... More >>us Cell Carcinoma Metastatic Head and Neck Squamous Cell Carcinoma Less <<	Phase 1 Phase 2	Terminated(early termination d... More >>ue to Sponsor decision (slow recruitment)) Less <<	-	-
NCT01708161	PIK3CA Mutated Advanced Solid ... More >>Tumors PIK3CA Amplified Advanced Solid Tumors Less <<	Phase 1 Phase 2	Terminated	-	United States, California ... More >> Novartis Investigative Site Los Angeles, California, United States, 90095 United States, Massachusetts Novartis Investigative Site Boston, Massachusetts, United States, 02114 United States, New York Novartis Investigative Site New York, New York, United States, 10017 United States, Tennessee Novartis Investigative Site Nashville, Tennessee, United States, 37203 Belgium Novartis Investigative Site Leuven, Belgium, 3000 Canada, Ontario Novartis Investigative Site Toronto, Ontario, Canada, M5G 1Z6 Spain Novartis Investigative Site Sevilla, Andalucia, Spain, 41013 Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Novartis Investigative Site Madrid, Spain, 28033 Novartis Investigative Site Madrid, Spain, 28041 Less <<
NCT01923168	Breast Cancer	Phase 2	Completed	-	-
NCT01923168	-		Completed	-	-
NCT01602315	-		Terminated(early termination d... More >>ue to Sponsor decision (slow recruitment)) Less <<	-	-
NCT03706573	-		-	-	-
NCT01708161	-		Terminated	-	-
NCT03056755	Breast Cancer	Phase 2	Recruiting	April 10, 2020	-
NCT03601507	CDKN2A-p16 Positive ... More >> Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 Less <<	Phase 2	Recruiting	December 31, 2022	United States, Arizona ... More >> The University of Arizona Medical Center-University Campus Recruiting Tucson, Arizona, United States, 85724 Contact: Julie E. Bauman 520-626-4101 jebauman@email.arizona.edu Principal Investigator: Julie E. Bauman Less <<
NCT02624557	Hepatic Impairment	PHASE1	COMPLETED	2017-10-01	DaVita Clinical Research-Denve... More >>r, Lakewood, Colorado, 80228, United States\|University of Miami / Clinical Research Services, Inc., Miami, Florida, 33136, United States\|Orlando Clinical Research Center, Orlando, Florida, 32809, United States\|DaVita Clinical Research, Minneapolis, Minnesota, 55404, United States Less <<
NCT02058381	Pre-menopausal Breast Cancer ... More >> PI3K Pathway Inhibition Less <<	Phase 1	Completed	-	Hong Kong ... More >> Novartis Investigative Site Hong Kong, Hong Kong Korea, Republic of Novartis Investigative Site Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620 Novartis Investigative Site Gyeonggi-do, Korea, Korea, Republic of, 10408 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 05505 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 06351 Novartis Investigative Site Seoul, Korea, Republic of, 03722 Taiwan Novartis Investigative Site Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan, 33305 Novartis Investigative Site New Taipei City, TWN, Taiwan, 23561 Novartis Investigative Site Kaohsiung City, Taiwan, 83301 Novartis Investigative Site Taichung, Taiwan, 407 Novartis Investigative Site Taipei, Taiwan, 10002 Novartis Investigative Site Taipei, Taiwan, 10449 Novartis Investigative Site Taipei, Taiwan, 112 Thailand Novartis Investigative Site Bangkok, Thailand, 10330 Novartis Investigative Site Chiang Mai, Thailand, 50200 Less <<
NCT02437318	Breast Cancer	Phase 3	Active, not recruiting	April 15, 2020	-
NCT03631953	Meningioma	Phase 1	Not yet recruiting	January 1, 2022	France ... More >> Assistance Publique Hôpitaux de Marseille Not yet recruiting Marseille, France, 13354 Contact: Thomas GRAILLON, PH 491385545 ext +33 thomas.graillon@ap-hm.fr Contact: Olivier CHINOT, PU-PH 491385545 ext +33 olivier.chinot@ap-hm.fr Principal Investigator: Thomas GRAILLON, PH Less <<
NCT03207529	Malignant Neoplasm of Breast	Phase 1	Not yet recruiting	January 2021	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact: Clinical Research Operations mskaruturi@mdanderson.org Less <<
NCT02077933	Neoplasms Bre... More >>ast Neoplasms Kidney Neoplasms Pancreatic Neuroendocine Neoplasms Less <<	Phase 1	Active, not recruiting	November 30, 2018	United States, Arkansas ... More >> Highlands Oncology Group Fayetteville, Arkansas, United States, 72703 United States, New York Memorial Sloan Kettering Cancer Center SC - BYL719Z2102 New York, New York, United States, 10065 France Novartis Investigative Site Bordeaux Cedex, France, 33075 Novartis Investigative Site Bordeaux, France, 33076 Novartis Investigative Site Villejuif Cedex, France, 94805 Germany Novartis Investigative Site Berlin, Germany, 12203 Novartis Investigative Site Essen, Germany, 45136 Novartis Investigative Site Essen, Germany, 45147 Novartis Investigative Site Hannover, Germany, 30625 Hong Kong Novartis Investigative Site Hong Kong, Hong Kong Hungary Novartis Investigative Site Budapest, Hungary, H-1077 Italy Novartis Investigative Site Ancona, AN, Italy, 60126 Novartis Investigative Site Milano, MI, Italy, 20141 Novartis Investigative Site Modena, MO, Italy, 41124 Novartis Investigative Site Verona, VR, Italy, 37126 Netherlands Novartis Investigative Site Amsterdam, Netherlands, 1066 CX Novartis Investigative Site Utrecht, Netherlands, 3584CX Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 Novartis Investigative Site Madrid, Spain, 28007 Novartis Investigative Site Madrid, Spain, 28034 United Kingdom Novartis Investigative Site Manchester, United Kingdom, M20 4BX Less <<
NCT03386162	Breast Cancer, PI3K, Alpelisib	Phase 2	Recruiting	July 1, 2023	France ... More >> Institut de Cancérologie de l'Ouest/Paul Papin Recruiting Angers, France Contact: Mario CAMPONE, MD, PhD mario.campone@ico.unicancer.fr Principal Investigator: Mario CAMPONE, MD, PhD Institut Sainte-Catherine Recruiting Avignon, France Contact: Alice Mege, MD Principal Investigator: Alice Mege, MD Institut Bergonié Recruiting Bordeaux, France Contact: Marc DEBLED, MD Principal Investigator: Marc DEBLED, MD Polyclinique Bordeaux Nord Aquitaine Recruiting Bordeaux, France Contact: Nadine DOHOLLOU, MD Centre François Baclesse Recruiting Caen, France Contact: Christelle Levy Principal Investigator: Christelle Levy, MD Centre Jean Perrin Recruiting Clermont-ferrand, France, 63011 Contact: Marie-Ange MOURET-REYNIER Principal Investigator: Marie Ange MOURET-REYNIER CH Alpes Leman Recruiting Contamine-sur-Arve, France Contact: Carol ALLIOT, MD Centre de Lutte Contre le Cancer Georges-Francois Leclerc Recruiting Dijon, France, 21079 Contact: Nicolas Isambert, MD 33-3-8073-7506 Chd Vendee Recruiting La Roche Sur Yon, France Contact: Tifenn L'HARIDON, MD Principal Investigator: Tifenn L'HARIDON, MD Centre Oscar Lambret Recruiting Lille, France Contact: Nuria KOTECKI, MD Principal Investigator: Nuria KOTECKI, MD CHU Dupuytren Recruiting Limoges, France Contact: Laurence VENAT-BOUVET, MD Centre Hospitalier Lyon Sud Recruiting Lyon, France Contact: Benoit You, MD Principal Investigator: Benoit You, MD Centre Leon Berard Recruiting Lyon, France Contact: Thomas BACHELOT, MD Principal Investigator: Thomas BACHELOT, MD Hôpital Privé Jean Mermoz Recruiting Lyon, France Contact: Olfa DERBEL, MD Institut Paoli Calmettes Recruiting Marseille, France Contact: Anthony Gonçalves, MD, PhD Principal Investigator: Anthony Gonçalves, MD, PhD CInstitut Regional du cancer-Centre Val D'Aurelle Recruiting Montpellier, France Contact: William JACOT, MD Principal Investigator: William JACOT, MD Centre Alexis Vautrin Recruiting Nancy, France Contact: Vicent Massard Principal Investigator: Vincent Massard, MD Institut de Cancérologie de l'Ouest/ René Gauducheau Recruiting Nantes, France Contact: Mario Campone, MD, PhD Principal Investigator: Mario Campone, MD, PhD Centre Antoine Lacassagne Recruiting Nice, France Contact: Jean-Marc Ferrero Principal Investigator: Jean-Marc Ferrero, MD Institut Curie Recruiting Paris, France Contact: Marie-Paule Sablin, MD mariepaule.sablin@curie.fr Principal Investigator: Marie-Paule Sablin, MD Centre Eugène Marquis Recruiting Rennes, France Contact: Claudia Lefeuvre Plesse Principal Investigator: Claudia Lefeuvre Plesse, MD Centre Henri Becquerel Recruiting Rouen, France Contact: Jean-Christophe Théry, MD Principal Investigator: Jean-Christophe Théry, MD Centre Rene Huguenin Recruiting Saint Cloud, France, 92211 Contact: Florence COUSSY, MD Chru Strasbourg - Nouvel Hopital Civil Recruiting Strasbourg, France Contact: Philippe BARTHELEMY, MD Principal Investigator: Philippe BARTHELEMY, MD Hôpitaux du Léman Recruiting Thonon-les-bains, France, 74200 Contact: Francesco DEL PIANO Principal Investigator: Francesco DEL PIANO CHI de Toulon - Hôpital Sainte-Musse Recruiting Toulon, France Contact: Xavier TCHIKNAVORIAN, MD Principal Investigator: Xavier TCHIKNAVORIAN, MD Institut Claudius Regaud Recruiting Toulouse, France Contact: Florence Dalenc, MD Principal Investigator: Florence Dalenc, MD Institut Gustave Roussy Recruiting Villejuif, France Contact: Monica ARNEDOS, MD Principal Investigator: Monica ARNEDOS, MD Less <<
NCT02620839	Solid Tumors	Phase 1	Recruiting	March 2020	United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94143-1711 Contact: Pamela N. Munster, MD 877-827-3222 cancertrials@ucsf.edu Less <<
NCT04980833	PIK3CA-related Overgrowth Spec... More >>trum (PROS) Less <<	PHASE2	ACTIVE_NOT_RECRUITING	2027-09-01	Boston Childrens Hospital ., B... More >>oston, Massachusetts, 02215, United States\|Novartis Investigative Site, Dijon, 21034, France\|Novartis Investigative Site, Montpellier, 34295, France\|Novartis Investigative Site, Paris 15, 75015, France\|Novartis Investigative Site, Dublin, 12, Ireland\|Novartis Investigative Site, Madrid, 28046, Spain Less <<
NCT03941782	Lymphangioma		NO_LONGER_AVAILABLE	-	University of New Mexico - Can... More >>cer Center, Albuquerque, New Mexico, 87106, United States Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed